Cost Curve

A Spring Reading List of Essential Research and Analyses

Brian Reid

CMS Targets Prior Auth Timelines for Medicines, Though High Denial Rates May Be the Bigger Issue

And BIO’s leader expresses concern about the MFN choices smaller biotechs must make

Brian Reid

A New Poll Underscores Patient Interest – and Payer Risk – in Medicare Coverage of GLP-1s for Obesity

Brian Reid

AbbVie Launches a New Legal Battle Over 340B, Challenging the Government Definition of ‘Patient’

Brian Reid

AbbVie Launches a New Legal Battle Over 340B, Challenging the Government Definition of ‘Patient’

Brian Reid

PCMA Survey Says Employers Love Their PBMs. But There Are Reasons to Be Skeptical.

Brian Reid

A New Analysis Makes Clear How Expensive It Will Be for Plans to Add Obesity Meds to Medicare

Plus, the crossover event of the year: TrumpRx is driving traffic to Mark Cuban Cost Plus Drugs

Brian Reid

Looking Past the Tariff Headlines to Focus on Where the Impact Is ... and Is Not

And the White House budget proposal includes a huge boost in funding to oversee 340B

Brian Reid

Lilly Wins FDA Approval for Its Foundayo Obesity Pill, Which Will Cost Between $149 and $349

Plus the drug industry gets a big appeals court win in the ongoing battle to set rules around 340B contract pharmacies

Brian Reid